Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 12/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3301612 | 0.91 | ACHE (0.52) | ACHE | |
| SCHEMBL3301607 | 0.91 | ACHE (0.52) | ACHE | |
| SCHEMBL3298372 | 0.84 | KDM1A (0.43) | ACHECA12CA1CA2CA7 | |
| SCHEMBL31303024 | 0.82 | TRPV1 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8185532 | 0.82 | TRPV1 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL24817021 | 0.82 | TRPV1 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31303000 | 0.82 | TRPV1 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31302986 | 0.82 | TRPV1 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3304298 | 0.82 | CA1 (0.44) | ACHECA12CA1CA2CA7 | |
| SCHEMBL3299002 | 0.81 | ACHE (0.47) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609719-B2 | Propargylated aminoindans, processes for preparation, and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2013-12-17 | — | — | US | disclosed |
| US-20100093848-A1 | PROPARGYLATED AMINOINDANS, PROCESSES FOR PREPARATION, AND USES THEREOF | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2010-04-15 | — | — | US | disclosed |
| US-7625946-B2 | Propargylated aminoindans, processes for preparation, and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2009-12-01 | — | — | US | disclosed |
| WO-2007100583-A2 | PROPARGYLATED AMINOINDANS, PROCESSES FOR PREPARATION, AND USES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-09-07 | — | — | WO | disclosed |
| US-20070203232-A1 | Propargylated aminoindans, processes for preparation, and uses thereof | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203232-A1 | Propargylated aminoindans, processes for preparation, and uses thereof | PRMT3, PRMT1, PNMT | ACHE 76/4885CA12 4790/4885CA1 3692/4885 |
| US-20100093848-A1 | PROPARGYLATED AMINOINDANS, PROCESSES FOR PREPARATION, AND USES THEREOF | DNPEP, PEPD, ACHE | ACHE 3/4885CA12 4142/4885CA1 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.